- Home
- MNPR vs PEO Comparison
MNPR vs PEO Comparison
Compare MNPR & PEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MNPR | PEO |
|---|---|---|
| Founded | 2014 | 1929 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 531.6M | 577.0M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | MNPR | PEO |
|---|---|---|
| Price | $76.19 | $21.65 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 13 | 0 |
| Target Price | ★ $97.83 | N/A |
| AVG Volume (30 Days) | ★ 163.8K | 35.4K |
| Earning Date | 11-13-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 5.93% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $21.00 | $19.22 |
| 52 Week High | $105.00 | $23.80 |
Technical Indicators
Market Signals| Indicator | MNPR | PEO |
|---|---|---|
| Relative Strength Index (RSI) | 42.10 | 52.06 |
| Support Level | $74.51 | $21.45 |
| Resistance Level | $79.31 | $21.94 |
| Average True Range (ATR) | 6.38 | 0.28 |
| MACD | -0.93 | 0.01 |
| Stochastic Oscillator | 6.10 | 72.59 |
Price Performance
Historical ComparisonAbout MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About PEO Adams Natural Resources Fund Inc.
Adams Natural Resources Fund Inc is a non-diversified U.S. equity fund that invests in liquid energy and other natural resources stocks. The Fund's investment objectives are preservation of capital, reasonable income, and opportunity for capital gain. A majority of its assets are invested in petroleum or natural resources industries or industries connected to them. It has broad flexibility to invest in stocks of varying capitalizations and predominantly invests in stocks found in the S&P 500 Energy and S&P 500 Materials sectors.